NEW YORK ( TheStreet) -- CHANGE IN RATINGS, EPS Agco ( AGCO) downgraded at BofA/Merrill from Buy to Neutral. Company is leveraged to the tractor market. $40 price target. Alexion Pharmaceuticals ( ALXN) rated new Overweight at JP Morgan. $81 price target. Soliris should continue to drive growth. Allegheny Technologies ( ATI) numbers reduced at Keybanc.Shares of ATI now seen reaching $60. Estimates also cut, given lower nickel prices. American Express ( AXP - Get Report) downgraded at Jefferies from Buy to Hold. New analyst expects higher credit losses in 2012. $50 price target. AMR ( AMR - Get Report) upgraded at Rodman & Renshaw from Market Perform to Outperform. $5 price target. Company is not likely to declare bankruptcy and is attractively valued following a 33% decline. Avon ( AVP) estimates, target cut at UBS. Shares of AVP now seen reaching $31. Estimates also lowered on FX weakness and deterioration in investor sentiment. Maintain Buy rating. Beam ( BEAM) upgraded at Goldman from Neutral to Buy. Company was also placed on the Conviction List. $50 price target. Company can continue to gain market share and buy back stock. Capital One ( COF - Get Report) downgraded at Jefferies from Buy to Hold. $40 price target. New analyst believes that the stock lacks near-term catalysts. Chipotle ( CMG) rated new Outperform at Credit Suisse. $370 price target. Company should continue to deliver solid growth in the coming quarters. Comcast ( CMCSA - Get Report) added to Analyst Focus List at JP Morgan. The cable business is solid and the company is making steady improvements at NBC Universal. $30 price target. Corning ( GLW - Get Report) estimates, target lowered at Citigroup.Shares of GLW now seen reaching $13. Estimates also lowered on negatively revised guidance. Edwards Lifesciences ( EW) estimates lowered at JP Morgan through 2015. Sapien could see fewer patients qualify for on-label usage. Underweight rating and $69 price target. Exelon ( EXC) upgraded at Citigroup from Hold to Buy. $48 price target. EPA related market tightening should benefit the company. Express Scripts ( ESRX) rated new Outperform at OppenheimerESRX was initiated with an Outperform rating, Oppenheimer said. $54 price target. Stock is already pricing in a potential near-term earnings shortfall. First Cash Financial ( FCFS) numbers cut at Sterne Agee.Shares of FCFS now seen reaching $38. Estimates also reduced, given currency headwinds. Underperform rating. Forest Oil ( FST) upgraded at Canaccord from Hold to Buy. $22 price target. Company has attractive assets, following the spin-off of its Canadian business. Goodyear Tire ( GT) downgraded to sell by TheStreet Ratings.
KMI) upgraded at Goldman from Neutral to Buy. Company was also placed on the Conviction List. $32 price target. Company offers a solid dividend yield as well as growth. Lorillard ( LO) downgraded at Goldman from Buy to Neutral. Valuation call, based on a $123 price target. Mastercard ( MA - Get Report) rated new Buy at Guggenheim Securities. Company can deliver above-average growth and deserves a premium valuation. McDermott ( MDR - Get Report) cut from Conviction Buy List at Goldman Sachs. Valuation call, based on a $17 price target. MetroPCS ( PCS) downgraded to hold by TheStreet Ratings. NRG ( NRG) estimates, target lowered at UBS.Shares of NRG now seen reaching $25. Estimates also cut on lowered guidance due to extreme heat in Texas. Maintain Buy rating. Pharmaceutical Product Development ( PPDI) downgraded at Citigroup from Buy to Hold. $33.25 price target. Company has entered a definitive merger agreement with The Carlyle Group and Hellman & Friedman. Ralph Lauren ( RL - Get Report) rated new Equal-weight at Morgan Stanley. Stock is already factoring in high expectations, despite macro uncertainty. Sirona Dental ( SIRO) upgraded at Jefferies from Hold to Buy. $57 price target. Valuation call, as the stock has sold off 27% since early July. Sonoco Products ( SON) downgraded at Argus from Buy to Hold. Sluggish economy has hurt packaging demand. Tiffany ( TIF - Get Report) estimates raised at Goldman through 2013. Company is leveraged to a stronger yen. Vertex Pharmaceuticals ( VRTX) upgraded at JMP to Market Outperform. $53 price target. Incivek should continue to drive near-term growth. VF Corp. ( VFC) rated new Outperform at Morgan Stanley. $148 price target. Company can double its sales through international growth. Visa ( V - Get Report) rated new Neutral at Guggenheim Securities. Valuation call, as the company could possibly lose market share in the debit card market. Wal-Mart ( WMT - Get Report) estimates cut at Goldman through 2013. Company could be hurt by the stronger dollar. Warnaco ( WRC) rated new Underweight at Morgan Stanley. $43 price target. Company lacks pricing power and is facing rising input costs. Wolverine World Wide ( WWW) estimates increased at Credit Suisse through 2013. Company is realizing higher margins. Outperform rating and $44 price target.